Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Yong‐Tae Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4842-6874; OpenAlex author ID A5100658306. Sources: OpenAlex.

Their work

Papers
32 (first author 4, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
79
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 4 papers · 2020: 2 papers · 2021: 4 papers · 2022: 4 papers · 2023: 2 papers · 2024: 5 papers · 2025: 1 paper

Papers 32

  1. ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167625↗
  2. Safety and Efficacy of Neoadjuvant SABR in Pancreatic Cancer: Effect of Magnetic Resonance Imaging-Guided Respiratory-Gated Adaptive Radiation Therapy. First author DOI 10.1016/j.adro.2023.101312↗
  3. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin leve… First author DOI 10.1038/s41416-023-02474-w↗
  4. Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum … First author DOI 10.1038/s41416-023-02520-7↗
  5. Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib. Co-author DOI 10.3390/cancers16051056↗
  6. Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. Co-author DOI 10.4062/biomolther.2023.109↗
  7. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Co-author DOI 10.1002/jhbp.1050↗
  8. Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Pancreatic Cancer Cells. Last author DOI 10.3390/cancers15092642↗
  9. Cytokine-Induced Killer Cell Immunotherapy Combined With Gemcitabine Reduces Systemic Metastasis in Pancreatic Cancer: An Analysis Using Preclinical Adjuvant T… Co-author DOI 10.1097/mpa.0000000000002176↗
  10. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic a… Last author DOI 10.1177/17588359221119539↗
  11. Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX. Co-author DOI 10.3389/fonc.2022.945829↗
  12. Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies. Last author DOI 10.5009/gnl210166↗
  13. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, p… Co-author DOI 10.1177/17588359211056179↗
  14. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching … Last author DOI 10.1186/s12885-021-08277-7↗
  15. Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Ca… Co-author DOI 10.3390/cancers13061196↗
  16. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. Co-author DOI 10.5009/gnl19182↗
  17. Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer. Last author DOI 10.1016/j.hbpd.2020.05.005↗
  18. Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach. Last author DOI 10.5306/wjco.v11.i9.747↗
  19. The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case-control study in a Korean nationwide cohort. Last author DOI 10.1002/cam4.2617↗
  20. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Co-author DOI 10.1002/jhbp.648↗
  21. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment. Co-author DOI 10.1186/s12885-019-6193-0↗
  22. Comparison of Adjuvant Chemotherapy and Chemoradiation Therapy Efficacy for Pancreatic Cancer After R0 Resection: A Propensity Score-Matched Analysis Last author DOI 10.21203/rs.2.12295/v1↗
  23. Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer. Last author DOI 10.5009/gnl18220↗
  24. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreati… Co-author DOI 10.1097/md.0000000000005702↗
  25. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer. Last author DOI 10.1111/jgh.13075↗
  26. The Author's Response: Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. First author DOI 10.3346/jkms.2016.31.9.1505↗
  27. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3346/jkms.2015.30.7.917↗
  28. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 p… Co-author DOI 10.1371/journal.pone.0078977↗
  29. The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318221c903↗
  30. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318249d62e↗
  31. Postoperative prognostic predictors of pancreatic ductal adenocarcinoma: clinical analysis and immunoprofile on tissue microarrays. Last author DOI 10.1245/s10434-012-2277-7↗
  32. Concurrent chemotherapy and pulsed high-intensity focused ultrasound therapy for the treatment of unresectable pancreatic cancer: initial experiences. Co-author DOI 10.3348/kjr.2011.12.2.176↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ji Kon Ryu · 28 shared papers, 2011–2025 · strength 3.29
  2. Sang Hyub Lee · 25 shared papers, 2012–2025 · strength 3.16
  3. Woo Hyun Paik · 21 shared papers, 2013–2025 · strength 2.80
  4. Jin Ho Choi · 11 shared papers, 2018–2024 · strength 1.43
  5. In Rae Cho · 8 shared papers, 2021–2025 · strength 1.40
  6. Jung Won Chun · 6 shared papers, 2019–2025 · strength 0.85
  7. Jin‐Young Jang · 6 shared papers, 2019–2024 · strength 0.82
  8. Wooil Kwon · 6 shared papers, 2019–2024 · strength 0.82
  9. Woo Jin Lee · 4 shared papers, 2022–2025 · strength 0.67
  10. Min Su You · 6 shared papers, 2018–2021 · strength 0.64
  11. Hongbeom Kim · 4 shared papers, 2019–2024 · strength 0.61
  12. Gunn Huh · 5 shared papers, 2018–2021 · strength 0.58
  13. J.H. Lee · 3 shared papers, 2022–2024 · strength 0.48
  14. Sang Kook Lee · 3 shared papers, 2022–2024 · strength 0.48
  15. Ja‐Lok Ku · 3 shared papers, 2022–2024 · strength 0.48
  16. Eui Kyu Chie · 2 shared papers, 2023–2024 · strength 0.38
  17. Si Young Song · 3 shared papers, 2017–2024 · strength 0.38
  18. Dong Uk Kim · 3 shared papers, 2017–2024 · strength 0.38
  19. Ho Gak Kim · 3 shared papers, 2017–2024 · strength 0.38
  20. Sang Myung Woo · 2 shared papers, 2022–2025 · strength 0.35
  21. Min Woo Lee · 2 shared papers, 2023–2024 · strength 0.34
  22. Sun‐Whe Kim · 4 shared papers, 2012–2021 · strength 0.33
  23. Chang‐Hwan Park · 2 shared papers, 2024 · strength 0.33
  24. Jae Woo Kim · 2 shared papers, 2024 · strength 0.33
  25. Eui Joo Kim · 2 shared papers, 2024 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.